| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CCD.10664 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fccd.10664 |
| https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.10664 | ||
| P698 | PubMed publication ID | 14571494 |
| P50 | author | Raimund Erbel | Q29999865 |
| Uta Dahmen | Q61159946 | ||
| P2093 | author name string | Olaf Dirsch | |
| Alfons Fischer | |||
| Yan Li Gu | |||
| Heinrich Wieneke | |||
| Thomas Sawitowski | |||
| Holger Brauer | |||
| Stefan Wnendt | |||
| P2860 | cites work | A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization | Q28202763 |
| A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group | Q28245560 | ||
| FK506 inhibition of histamine release and cytokine production by mast cells and basophils | Q28370871 | ||
| Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study | Q32033266 | ||
| FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle | Q34463962 | ||
| Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation | Q38303363 | ||
| NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes | Q40693171 | ||
| Effects of L-749,329, an ET(A)/ET(B) endothelin receptor antagonist, in a porcine coronary artery injury model of vascular restenosis | Q40813916 | ||
| Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells | Q40968341 | ||
| Coronary intimal proliferation after balloon injury and stenting in swing: An animal model of restenosis | Q41771381 | ||
| Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). | Q43640832 | ||
| Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model | Q43727885 | ||
| Pathological analysis of local delivery of paclitaxel via a polymer-coated stent | Q43978575 | ||
| Pharmacokinetics of tacrolimus in liver transplant patients. | Q52350107 | ||
| Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction. | Q53746519 | ||
| Clinical and angiographic outcome after coronary arterial stenting with the carbostent. | Q53914247 | ||
| Preparation and in vivo testing of porous alumina ceramics for cell carrier applications. | Q53919635 | ||
| Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. | Q54341335 | ||
| Tacrolimus | Q60361316 | ||
| Compliance as a factor effecting the patency of a copolyurethane vascular graft | Q67355746 | ||
| Percutaneous polymeric stents in porcine coronary arteries. Initial experience with polyethylene terephthalate stents | Q67573978 | ||
| Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model | Q67733219 | ||
| Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin | Q71657027 | ||
| Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months | Q73321703 | ||
| Gold-coated NIR stents in porcine coronary arteries | Q73396816 | ||
| Biocompatibility of alumina ceramic and polyethylene as materials for pivot bearings of a centrifugal blood pump | Q73593729 | ||
| Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation | Q73662537 | ||
| Recurrent unstable angina after directional coronary atherectomy is related to the extent of initial coronary plaque inflammation | Q73744984 | ||
| Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial | Q74009372 | ||
| In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia | Q74027568 | ||
| In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity | Q74272164 | ||
| Experimental studies of the biological response to a new bone cement: II Soft tissue reactions in the rat | Q74829045 | ||
| Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group | Q77620829 | ||
| First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome | Q78068408 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cardiology and cardiovascular medicine | Q96320350 |
| P304 | page(s) | 399-407 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Catheterization and Cardiovascular Interventions | Q2352240 |
| P1476 | title | Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits | |
| P478 | volume | 60 |
| Q46583403 | Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model |
| Q36968009 | Delivery of large biopharmaceuticals from cardiovascular stents: a review |
| Q41562461 | Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriers |
| Q36815941 | Drug delivery via nano-, micro and macroporous coronary stent surfaces. |
| Q37144221 | Drug-eluting stents - what should be improved? |
| Q36417437 | Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis? |
| Q33686400 | Effects of nanoporous alumina on inflammatory cell response |
| Q30475719 | Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases |
| Q33839384 | Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques |
| Q37397959 | Enhancing Stent Effectiveness with Nanofeatures |
| Q30842800 | Influence of nanoporesize on platelet adhesion and activation |
| Q40281019 | Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides? |
| Q28654633 | Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention |
| Q38154806 | Macroscale delivery systems for molecular and cellular payloads. |
| Q58621682 | Mesoporous alumina as a biomaterial for biomedical applications |
| Q36344315 | Microfabrication and nanotechnology in stent design |
| Q38816692 | Nanomaterial coatings applied on stent surfaces |
| Q38034812 | Nanomedicine in cardiovascular therapy: recent advancements |
| Q30356581 | Nanomedicine: Addressing Cardiovascular Disease and Cardiovascular Tissue Regeneration. |
| Q28220309 | Nanoparticulate carriers for the treatment of coronary restenosis |
| Q59018393 | Nanoporous Aluminium Oxide Membranes as Cell Interfaces |
| Q35017593 | Nanoscale surface modifications of medically relevant metals: state-of-the art and perspectives. |
| Q30362371 | Nanotechnology in diagnosis and treatment of coronary artery disease. |
| Q37701260 | New drug-eluting stent concepts |
| Q33478827 | Procoagulant behavior and platelet microparticle generation on nanoporous alumina |
| Q36640339 | Progressive stent technologies: new approaches for the treatment of cardiovascular diseases |
| Q46731602 | Reduced oxidative stress in primary human cells by antioxidant released from nanoporous alumina |
| Q37622244 | Self-ordered nanopore and nanotube platforms for drug delivery applications. |
| Q44558338 | Stent-based drug-delivery systems: current challenges and future trends |
| Q37872741 | Stents as a platform for drug delivery |
| Q38040738 | Surface chemical and physical modification in stent technology for the treatment of coronary artery disease |
| Q50507385 | Sustained Release of Cx43 Antisense Oligodeoxynucleotides from Coated Collagen Scaffolds Promotes Wound Healing. |
| Q36405134 | The cell cycle: a critical therapeutic target to prevent vascular proliferative disease |
| Q38505371 | The development of carotid stent material |
| Q28066800 | TiO2 nanotube platforms for smart drug delivery: a review |
| Q38265789 | Titania nanotube arrays for local drug delivery: recent advances and perspectives |
Search more.